Search

Search Constraints

You searched for: Author/Creator Scearce‐Levie, Kimberly

Search Results

1. DNL104, a Centrally Penetrant RIPK1 Inhibitor, Inhibits RIP1 Kinase Phosphorylation in a Randomized Phase I Ascending Dose Study in Healthy Volunteers. Issue 2 (25th September 2019)

2. Fibrillar Aβ causes profound microglial metabolic perturbations in a novel APP knock‐in mouse model. (1st February 2022)

3. Fibrillar Aβ causes profound microglial metabolic perturbations in a novel APP knock‐in mouse model. (December 2021)

4. Longitudinal biomarkers in amyotrophic lateral sclerosis. Issue 7 (9th June 2020)

5. P1‐359: WIDESPREAD BRAIN DISTRIBUTION AND ROBUST BACE1 INHIBITION FOLLOWING INTRACEREBROVENTRICULAR INFUSION OF ANTI‐BACE1 IN NON‐HUMAN PRIMATES. (1st July 2014)

6. P2–399: Modest reductions in BACE1 activity significantly reduce beta‐amyloid plaque load and neuroinflammation in a mouse model of Alzheimer's disease. (1st July 2013)

7. Safety, pharmacokinetics and target engagement of novel RIPK1 inhibitor SAR443060 (DNL747) for neurodegenerative disorders: Randomized, placebo‐controlled, double‐blind phase I/Ib studies in healthy subjects and patients. Issue 8 (1st June 2022)

8. Widespread brain distribution and activity following i.c.v. infusion of anti‐β‐secretase (BACE1) in nonhuman primates. (6th October 2017)